Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
Updated Jun 2, 2023 04:00 PM ET
After-Market: $11.09 0.00 (0.00%) 6:54 PM ET
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
|Zacks Rank||Definition||Annualized Return|
Zacks Rank Education - Learn about the Zacks Rank
Zacks Rank Home - Zacks Rank resources in one place
Zacks Premium - The only way to fully access the Zacks Rank
3-Hold of 5 3
The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.
The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.
Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.
As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.
Zacks Style Scores Education - Learn more about the Zacks Style Scores
F Value F Growth F Momentum F VGM
The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.
An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.
The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.
Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank
Price and Consensus
The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.
The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.
The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.
Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.
Learn more about Zacks Equity Research reports
TBPH 11.09 -0.04(-0.36%)
Will TBPH be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
About Price and Consensus
The Price and Consensus chart displays the company's stock price along with the consensus estimate. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES
Zacks News for TBPH
Theravance's (TBPH) Q1 Earnings and Revenues Miss Estimates
Theravance Biopharma (TBPH) Reports Q1 Loss, Misses Revenue Estimates
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
Will Molecular Templates Inc. (MTEM) Report Negative Q1 Earnings? What You Should Know
Corcept Therapeutics (CORT) Lags Q1 Earnings Estimates
Earnings Preview: Theravance Biopharma (TBPH) Q1 Earnings Expected to Decline
Other News for TBPH
SVB Securities Remains a Buy on Theravance Biopharma (TBPH)
Theravance Biopharma, Inc. Announces Orphan Drug Designation Granted to Ampreloxetine for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophy
Theravance Biopharma`s ampreloxetine designated for FDA orphan status
Analysts Offer Insights on Healthcare Companies: Palatin Technologies (PTN), ANI Pharmaceuticals (ANIP) and Theravance Biopharma (TBPH)
Theravance Biopharma price target raised to $20 from $19 at H.C. Wainwright